Conclusions on the position of urapidil.
van Zwieten
P A
PA
Division of Pharmacotherapy, University of Amsterdam, The Netherlands.
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D010879:Piperazines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D010879:Piperazines; C015568:urapidil